The European neural implants market is estimated to record a solid CAGR of 7.2% during the forecast period (2021-2027). The healthcare system in this region is advanced, highly regulated, sophisticated, and evolved with a standard reimbursement structure. The increasing government expenditure on health care is also contributing to the market growth. For instance, in May 2016, the European Commission announced to establish 14 new primary healthcare centers across Ireland supported by the investment plan of Europe. In addition, the region is home to some of the best and most established health care systems across the globe.
Browse the full report description European Neural Implants Market Size, Share & Trends Analysis Report by Product (Deep Brain Stimulation (DCS), Spinal Cord Stimulation (SCS), and Vagus Nerve Stimulation (VNS)), by Application (Chronic Pain, Epilepsy, Parkinson's Disease (PD), and Others (Depression and Other Movement Disorders)), and by End-user (Hospitals, Outpatient Surgery Centers, and Specialized Neurological Centers (SNCs)) Forecast Period (2021-2027) at https://www.omrglobal.com/request-sample/europe-neural-implants-market
In the region, the public, universal provision as the norm and standards offers very high scale infrastructure. In addition, the booming private sector caters to people who want extra comforts, choice, and shorter waiting times. Such favorable initiatives by both private and government bodies are fueling the market growth of advanced treatment options such as minimally invasive procedures of brain implants, thereby contributing to the overall neural implants market in Europe. Further, the increasing adoption of remote health care, virtual care, mobile health, and e-health made neural implant procedures more feasible with the help of the latest devices that made an easy transfer of medical data using several digital platforms.
Also, one of the primary factors driving the neural implants market in Europe is the availability of a broad range of neural implants for treating neurological disorders. Most of the companies offer a diverse range of neural implants in the region. For instance, prominent players such as s, Aleva Neurotherapeutics, gained CE Mark for the directSTIM DBS System in December 2019. Further, Nuvectra gained CE Mark in January 2019 for the Full body MR-conditional approval for the Company’s Algovita SCS system. Likewise, in September 2019, Saluda Medical received CE Mark for the Evoke, the first & only available ECAP-controlled, closed-loop SCS system for chronic pain. Therefore, such wider product availability in Europe is driving the growth of the neural implants market.
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
European Neural Implants Market Report Segment
By Product
By Application
By End-user
European Neural Implants Market Report Segment
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/industry-reports/europe-neural-implants-market